I was on the computer just now and came accross this loperamide-aripiprazole hybrid:
Bonifazi A, Battiti FO, Sanchez J, Zaidi SA, Bow E, Makarova M, Cao J, Shaik AB, Sulima A, Rice KC, Katritch V, Canals M, Lane JR, Newman AH. Novel Dual-Target μ-Opioid Receptor and Dopamine D3 Receptor Ligands as Potential Nonaddictive Pharmacotherapeutics for Pain Management. J Med Chem. 2021 Jun 10;64(11):7778-7808. doi: 10.1021/acs.jmedchem.1c00611. Epub 2021 May 20. PMID: 34011153; PMCID: PMC9308496.
Disclosed herein are novel dual-target compounds that bind at both the mu-opioid receptor (MOR) and dopamine D3 receptors (D3R) to provide MOR-mediated analgesia, while minimizing addictive liability through D3R antagonism/partial agonism. The novel compounds are useful in the treatment of pain...
patents.google.com